Surgery Partners, Inc. (NASDAQ: SGRY), a prominent player in the healthcare sector, is drawing attention with its potential for a 32.15% upside, according to recent analyst ratings. As a key operator in the medical care facilities industry, Surgery Partners provides a network of surgical facilities and ancillary services across the United States, specializing in various non-emergency surgical procedures.
Currently trading at $14.24, the stock is positioned near the lower end of its 52-week range of $11.49 to $22.94. This presents an intriguing opportunity for investors, especially with an average analyst target price of $18.82, which suggests significant growth potential. The company’s market capitalization stands at $1.86 billion, reflecting its substantial footprint in the healthcare sector.
While Surgery Partners does not currently report a trailing P/E ratio, its forward P/E of 50.86 indicates a premium valuation based on expected earnings growth. However, the absence of other valuation metrics like PEG, Price/Book, and EV/EBITDA suggests that investors might need to look deeper into qualitative factors and growth prospects to assess its true value.
The company’s recent financial performance reveals a modest revenue growth of 2.70%. Despite a negative EPS of -0.69, Surgery Partners has demonstrated a Return on Equity (ROE) of 2.32%, alongside a robust free cash flow of $183.6 million. These figures highlight a company that, while currently unprofitable on a net income basis, is generating substantial cash flow to potentially fuel future growth or strategic investments.
Notably, Surgery Partners does not offer a dividend, as indicated by a 0.00% dividend yield and payout ratio. This aligns with its growth-driven strategy, where reinvestment into the business takes precedence over shareholder payouts.
Investor sentiment around Surgery Partners is largely optimistic, with 9 buy ratings and 3 hold ratings, and no sell ratings from analysts. This confidence is further bolstered by a favorable target price range of $14.00 to $24.00. However, investors should consider the company’s technical indicators. The stock’s 50-day and 200-day moving averages are slightly above its current price, and an RSI of 70.42 suggests the stock is nearing overbought territory, which could lead to short-term price corrections.
Surgery Partners’ MACD of -0.14, compared to a signal line of -0.17, indicates a bearish momentum in the immediate term, warranting caution for momentum traders. However, for long-term investors, the company’s comprehensive service offerings and strategic focus on non-emergency surgical procedures provide a stable foundation for growth.
Founded in 2004 and headquartered in Brentwood, Tennessee, Surgery Partners continues to expand its presence in the healthcare landscape. Its diversified portfolio, including ambulatory surgery centers and surgical hospitals, positions it well to capitalize on growing demand for specialized medical services.
Investors considering adding Surgery Partners to their portfolios should weigh the company’s growth prospects against its current valuation metrics and market conditions. With a solid operational base and a strategic focus on high-demand medical specialties, Surgery Partners, Inc. presents itself as a compelling opportunity for those seeking exposure to the evolving healthcare sector.
